Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Blueprint Medicines

Chart of the Day: Does Blueprint Medicines Have a Blueprint for Success?

The Chart of the Day belongs to the cancer biomedical company Blueprint Medicines (BPMC) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the...

Barchart · Dec 13, 2023

Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022

Upgrades

Benzinga · Nov 2, 2022

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga · Aug 17, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

This Analyst Thinks Blueprint Medicines' Non-Dilutive Funding 'Deflates M&A Speculation'

Today Blueprint Medicines Corp (NASDAQ:BPMC) announced strategic financing agreements with Sixth Street and Royalty Pharma Plc (NASDAQ:RPRX) for up to $1.25 billion, including $575 million upfront upon deal closure. SVB Securities thinks the terms of the deals are fairly valued on the Sixth Street portion and favorable for Blueprint Medicines on the Royalty Pharma portion. "In addition,…

Benzinga · Jun 30, 2022

What 7 Analyst Ratings Have To Say About Blueprint Medicines

Within the last quarter, Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings:

Benzinga · Jun 27, 2022

SVB Leerink Maintains Market Perform Rating for Blueprint Medicines: Here's What You Need To Know

SVB Leerink has decided to maintain its Market Perform rating of Blueprint Medicines (NASDAQ:BPMC) and lower its price target from $82.00 to $60.00. Shares of Blueprint Medicines are trading down 8.32% over the last 24 hours, at $44.07 per share.

Benzinga · Jun 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2022

Benzinga · Jun 10, 2022

Read news from The Economist, FT, and more,
with one subscription

4 Analysts Have This to Say About Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Benzinga · Jun 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

Upgrades

Benzinga · Jun 1, 2022

What 3 Analyst Ratings Have To Say About Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) has observed the following analyst ratings within the last quarter:

Benzinga · May 19, 2022

Blueprint Medicines: Q1 Earnings Insights

Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Tuesday, May 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 3, 2022

Earnings Preview: Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.94.

Benzinga · May 2, 2022

Blueprint Medicines Q1 2022 Earnings Conference Call On May 3, 2022 At 08:30 AM ET

Blueprint Medicines (NASDAQ:BPMC) will host a conference call at 08:30 AM ET on May 3, 2022, to discuss Q1 2022 earnings results.

Benzinga · Apr 27, 2022

Where Blueprint Medicines Stands With Analysts

Over the past 3 months, 6 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Apr 13, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Mar 1, 2022

What 5 Analyst Ratings Have To Say About Blueprint Medicines

Over the past 3 months, 5 analysts have published their opinion on Blueprint Medicines (NASDAQ:BPMC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga · Feb 28, 2022

Blueprint Medicines, Proteovant Collaboration For Protein Degrader Therapies

Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics have entered a

Benzinga · Feb 17, 2022

Where Blueprint Medicines Stands With Analysts

Benzinga · Feb 15, 2022

Earnings Preview: Blueprint Medicines

Blueprint Medicines (NASDAQ:BPMC) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that Blueprint Medicines will report an earnings per share (EPS) of $-1.65.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jan 28, 2022

EMA's Advisory Committee Recommends Approval Of Blueprint Medicines' Avapritinib In Blood Disorder

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has

Benzinga · Jan 25, 2022

Analyst Ratings For Blueprint Medicines

Analysts have provided the following ratings for Blueprint Medicines (NASDAQ:BPMC) within the last quarter:

Coverage From

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.